^{February 2026}

This retrospective analysis of the phase 3 TRANSFORM study assessed the impact of inflammatory risk, as defined by the InflaMix model, on outcomes in adults with second-line relapsed or refractory large B-cell lymphoma (LBCL). InflaMix classifies patients as inflamed or noninflamed based on routine laboratory parameters.

Results: In the second-line setting, most patients were classified as noninflamed. Among patients treated with Breyanzi, progression-free survival (PFS) was comparable between inflamed and noninflamed subgroups, indicating consistent efficacy regardless of inflammatory status (33.2 versus 30.9 months, p = 0.29). Across both InflaMix groups, Breyanzi resulted in longer median PFS than standard of care (SOC). In the noninflamed group, median PFS was 30.9 months with Breyanzi versus 5.7 months with SOC (p = 0.003). Inflamed patients treated with Breyanzi had a median PFS of 33.2 months versus 2.1 months for those treated with SOC (p = 0.146). the lack of statistical significance was likely due to limited patient numbers in the inflamed group for both arms. The lack of statistical significance was likely due to limited patient numbers in the inflamed group.Safety outcomes, including cytokine release syndrome and neurological events, were similar across InflaMix groups.

Conclusion: These findings indicate that Breyanzi delivers deep and durable clinical benefit in second-line R/R LBCL independent of inflammatory risk, supporting its use as an effective treatment option across biologically distinct patient subgroups.